Eurofarma starts selling weight loss pens across the country with a significant price reduction, expanding access

Brazilian pharmaceutical company Eurofarma announced this Tuesday, May 30, the start of sales of weight loss pens at lower prices throughout the country. The new price list, which foresees R$295 for initial doses and R$309 for treatment maintenance doses, represents a drop of almost 50% and was recently announced by the company. To illustrate the difference, similar products such as Ozempic and Wegovy, manufactured by the Danish Novo Nordisk, are usually sold for 975 reais and 1,399 reais, respectively.
With this initiative, Eurofarma seeks to expand access to therapies based on semaglutide, the active compound present in the pens. The focus is to serve patients diagnosed with overweight accompanied by comorbidities, obesity, type 2 diabetes and fatty liver, conditions that require continuous and accessible treatment.
The most affordable price for the weight loss pen is made possible through EuroCuida, a company loyalty program that requires interested users to register in advance. It is important to note that the participation of pharmacies in the program is not universal, and the complete list of units that have joined can be consulted on the digital channels maintained by Eurofarma.
Launched in April with a competitive price proposal, the platform aims not only to make the medicine more accessible, but also to ensure continuity of treatment, a crucial factor considering that obesity is recognized as a chronic disease. Until last month, the program had already registered more than 80 thousand people interested in its benefits.






